IGC Receives U.S. Patent for Method and Composition for Treating Seizure Disorders
June 08 2022 - 9:03PM
Business Wire
India Globalization Capital, Inc. (the “Company”) (NYSE
American: IGC) announced today that the United States Patent and
Trademark Office (“USPTO”) issued a patent (#11,351,152) to the
Company titled “Method and Composition for Treating Seizure
Disorders.”
The patent is assigned to IGC and relates to compositions and
methods for treating multiple types of seizure disorders and
epilepsy in humans and animals, using a combination of the
cannabinoid cannabidiol (CBD) with other compounds. Subject to
further research and study, the combination is intended to reduce
side effects caused by hydantoin anticonvulsant drugs such as
phenobarbital, by reducing the dosing of anticonvulsant drugs in
humans, dogs, and cats.
About 50 million people worldwide are affected by epilepsy (WHO,
2022). Of the approximately 76 million dogs in the U.S. (American
Veterinary Medical Association, 2018), about 5% (one in 20 dogs),
or about 3.8 million dogs, can suffer from seizures (Today’s
Veterinary Practice, 2014). The Company’s current plans are to
pursue a veterinarian pathway through observational studies and
clinical trials aimed towards developing a potential treatment for
seizure disorders in dogs and cats.
About IGC:
India Globalization Capital, Inc. (IGC), headquartered in
Maryland, engages in the development of cannabinoid-based therapies
for healthcare applications. IGC recently completed the first Phase
1 safety and tolerability clinical trial for patients suffering
from Alzheimer’s disease using a THC-based investigational new drug
candidate. The Company also operates an infrastructure business
based in India. www.igcinc.us, www.igcpharma.com.
Forward-Looking Statements:
This press release contains forward-looking statements. These
forward-looking statements are based largely on IGC’s expectations
and are subject to several risks and uncertainties, certain of
which are beyond IGC’s control. Actual results could differ
materially from these forward-looking statements as a result of,
among other factors, the Company’s failure or inability to
commercialize one or more of the Company’s products or
technologies, including the product or formulation described in
this release, or failure to obtain regulatory approval for the
product or formulation, where required; general economic conditions
that are less favorable than expected, including as a result of the
ongoing COVID-19 pandemic; the FDA’s general position regarding
cannabis- and hemp-based products; and other factors, many of which
are discussed in IGC’s SEC filings. IGC incorporates by reference
the human trial disclosures and Risk Factors identified in its
Annual Reports on Form 10-K filed with the SEC on June 14, 2021,
and Quarterly Reports on Form 10-Q, filed with the SEC on August
11, 2021, and October 29, 2021 as if fully incorporated and
restated herein. In light of these risks and uncertainties, there
can be no assurance that the forward-looking information contained
in this release will occur.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220608006202/en/
Claudia Grimaldi info@igcinc.us 301-983-0998
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Mar 2024 to Apr 2024
IGC Pharma (AMEX:IGC)
Historical Stock Chart
From Apr 2023 to Apr 2024